Related Experiment Videos

Use of beta-blockers for uncomplicated hypertension in the elderly: a cause for concern

K Tu1, N R C Campbell, Z Chen

  • 1Institute for Clinical Evaluative Sciences, Toronto, Canada.

Journal of Human Hypertension
|February 9, 2007
PubMed

Insights

Beta-blockers are less effective for elderly hypertension patients. Physicians should prioritize other antihypertensive drugs for initial treatment in older adults to improve outcomes.

Area of Science:

  • Gerontology
  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are a common first-line treatment for hypertension.
  • Evidence suggests beta-blockers may be less effective than other antihypertensives in the elderly.
  • Optimal initial pharmacotherapy for hypertension in older adults requires further investigation.

Purpose of the Study:

  • To identify characteristics of elderly hypertensive patients prescribed beta-blockers as first-line therapy.
  • To understand prescribing patterns for initial hypertension management in the elderly population.
  • To inform clinical practice guidelines regarding antihypertensive drug selection in older adults.

Main Methods:

  • Retrospective population-based cohort study utilizing data from Ontario, Canada (1994-2002).
  • Inclusion criteria: elderly patients (≥66 years) without comorbidities, newly treated for hypertension.
  • Multivariate analysis to determine factors associated with beta-blocker prescription as the initial antihypertensive agent.

Main Results:

  • 13% of 194,761 elderly patients received a beta-blocker as their first antihypertensive agent.
  • Male sex, younger age (66-69 years), long-term care residence, and lower socioeconomic status were associated with beta-blocker prescription.
  • Patients with diabetes were significantly less likely to be prescribed beta-blockers (OR 0.42).

Conclusions:

  • Prescribing patterns for initial antihypertensive therapy in the elderly do not consistently align with evidence suggesting beta-blockers' lower efficacy.
  • Physician education is needed to promote the selection of alternative antihypertensive agents for initial treatment in older patients with uncomplicated hypertension.
  • Further research should focus on optimizing hypertension management strategies for the elderly population.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...